Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 146-153

  Boonstra, Geartsje ^a   Van Haren, Neeltje E M ^a   Schnack, Hugo G ^a   Cahn, Wiepke ^a   Burger, Huibert ^a,b   Boersma, Maria ^a   De Kroon, Bart ^a   Grobbee, Diederick E ^a   Hulshoff Pol, Hilleke E ^a   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

antipsychotic agents; follow up studies; magnetic resonance imaging; schizophrenia; withholding treatment

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN THIRD VENTRICLE; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; IMAGE ANALYSIS; LATERAL BRAIN VENTRICLE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; WHITE MATTER;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79952441953     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820e3f58     Document Type: Article

References (59)

1. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157(1): 16-25. (Pubitemid 30027416)
2. Cahn W, Hulshoff Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry. 2002;59(11):1002-1010.
3. DeLisi LE, Sakuma M, Tew W, et al. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997;74(3):129-140. (Pubitemid 27315863)
4. Gur RE, Cowell P, Turetsky BI, et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry. 1998;55(2):145-152. (Pubitemid 28087600)
5. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008;34(2):354-366. (Pubitemid 351323347)
6. Pantelis C, Yucel M, Wood SJ, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull. 2005; 31(3):672-696. (Pubitemid 41253318)
7. Job DE, Whalley HC, Johnstone EC, et al. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage. 2005;25(4):1023-1030. (Pubitemid 40591646)
8. Cahn W, van Haren NE, Hulshoff Pol HE, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 2006;189:381-382. (Pubitemid 44606754)
9. Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry. 2001;49(6): 487-499. (Pubitemid 32226407)
10. Buchsbaum MS, Shihabuddin L, Brickman AM, et al. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophr Res. 2003;64(1):53-62. (Pubitemid 37153349)
11. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008;63(1):106-113. (Pubitemid 350234880)
12. Dorph-Petersen KA, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30(9): 1649-1661. (Pubitemid 43086022)
13. Haren VNE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;2057-2066. (Pubitemid 47417696)
14. Molina V, Reig S, Sanz J, et al. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res. 2005;80(1):61-71. (Pubitemid 41587464)
15. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361-370. (Pubitemid 40471685)
16. Keshavan MS, Rosenberg D, Sweeney JA, et al. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry. 1998;155(6):774-778. (Pubitemid 28252656)
17. Keshavan MS, Bagwell WW, Haas GL, et al. Changes in caudate volume with neuroleptic treatment. Lancet. 1994;344(8934):1434. (Pubitemid 24365327)
18. Scheepers FE, de Wied CC, Hulshoff Pol HE, et al. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology. 2001;24(1):47-54.
19. Lang DJ, Kopala LC, Vandorpe RA, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry. 2004;161(10):1829-1836. (Pubitemid 39314677)
20. Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry. 1999;156(8):1200-1204. (Pubitemid 29374879)
21. Heitmiller DR, Nopoulos PC, Andreasen NC. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr Res. 2004;66(27-3):137-142. (Pubitemid 38041111)
22. Glenthoj A, Glenthoj BY, Mackeprang T, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 2007;154(3):199-208. (Pubitemid 46428524)
23. Tauscher-Wisniewski S, Tauscher J, Christensen BK, et al. Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis. J Psychiatr Res. 2005;39(4):365-370. (Pubitemid 40404085)
24. Massana G, Salgado-Pineda P, Junque C, et al. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J Clin Psychopharmacol. 2005;25(2):111-117. (Pubitemid 40395088)
25. Chakos MH, Lieberman JA, Alvir J, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 1995;345(8947):456-457.
26. Crespo-Facorro B, Roiz-Santianez R, Perez-Iglesias R, et al. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1936-1943.
27. Frazier JA, Giedd JN, Kaysen D, et al. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry. 1996;153(4):564-566. (Pubitemid 26113325)
28. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):23.
29. Kuipers E, Kendall T, Antoniou J, et al. Schizophrenia (update). National Clinical Practice Guideline Number 82. London, UK: National Collaborating Centre for Mental Health. National Clinical Practice Guideline; 2009.
30. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
31. Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
32. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. 3-Dimensional Propositional System: An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme; 1988.
33. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87-97. (Pubitemid 128742012)
34. Schnack HG, Hulshoff HE, Baare WF, et al. Automatic segmentation of the ventricular system from MR images of the human brain. Neuroimage. 2001;14(1 Pt 1):95-104. (Pubitemid 32564889)
35. Schnack HG, Hulshoff Pol HE, Baare WF, et al. Automated separation of gray and white matter from MR images of the human brain. Neuroimage. 2001;13(1):230-237. (Pubitemid 34188260)
36. Staal WG, Hulshoff Pol HE, Schnack HG, et al. Structural brain abnormalities in patients with schizophrenia and their healthy siblings. Am J Psychiatry. 2000;157(3):416-421. (Pubitemid 30145928)
37. Chua SE, Deng Y, Chen EY, et al. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychol Med. 2009;39(5):793-800.
38. Degreef G, Ashtari M, Wu HW, et al. Follow-up MRI study in first episode schizophrenia. Schizophr Res. 1991;5(3):204-206.
39. Deng MY, McAlonan GM, Cheung C, et al. A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naive, newly diagnosed schizophrenia. Psychopharmacology (Berl). 2009;206(3):437-446.
40. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58(1):62-66. (Pubitemid 40909937)
41. Ho BC, Andreasen NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60(6):585-594. (Pubitemid 36682316)
42. McClure RK, Carew K, Greeter S, et al. Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophr Res. 2008;98(1-3):29-39. (Pubitemid 350235881)
43. Milev P, Ho BC, Arndt S, et al. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry. 2003;54(6):608-615. (Pubitemid 41115097)
44. Tauscher-Wisniewski S, Tauscher J, Logan J, et al. Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study. Schizophr Res. 2002;58(2-3):185-188. (Pubitemid 35284509)
45. Chua SE, Cheung C, Cheung V, et al. Cerebral grey, white matter and CSF in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89(1-3):12-21. (Pubitemid 44895585)
46. Jayakumar PN, Venkatasubramanian G, Gangadhar BN, et al. Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(4):587-591. (Pubitemid 40603835)
47. Ohrmann P, Siegmund A, Suslow T, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41(8):625-634. (Pubitemid 46509646)
48. Venkatasubramanian G, Jayakumar PN, Gangadhar BN, et al. Neuroanatomical correlates of neurological soft signs in antipsychotic-naive schizophrenia. Psychiatry Res. 2008;164(3): 215-222.
49. Cahn W, Hulshoff Pol HE, Bongers M, et al. Brain morphology in antipsychotic-naive schizophrenia: a study of multiple brain structures. Br J Psychiatry Suppl. 2002;43:s66Ys72.
50. Gur RE, Maany V, Mozley PD, et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry. 1998;155(12):1711-1717. (Pubitemid 28547495)
51. John JP, Burgess PW, Yashavantha BS, et al. Differential relationship of frontal pole and whole brain volumetric measures with age in neuroleptic-naive schizophrenia and healthy subjects. Schizophr Res. 2009;109(1-3):148-158.
52. Salgado-Pineda P, Baeza I, Perez-Gomez M, et al. Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. Neuroimage. 2003; 19(2 Pt 1):365-375. (Pubitemid 39665687)
53. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med. 2009; 39(11):1763-1777.
54. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. 2004;130(1):71-78. (Pubitemid 38221558)
55. Drake RJ. Insight into illness: impact on diagnosis and outcome of nonaffective psychosis. Curr Psychiatry Rep. 2008;10(3):210-216.
56. Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry. 2007;52(3):146-157. (Pubitemid 46761957)
57. Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol. 2008;22(8):882-894.
58. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry. 1996;57(suppl 11):4-11.
59. Tauscher J, Kufferle B, Asenbaum S, et al. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl). 2002;162(1):42-49. (Pubitemid 34639555)